Scribe Therapeutics Presents Epigenetic X-Repressor Data at 2025 Keystone Symposium Scribe Therapeutics Inc. (Scribe), a leading genetic medicines company leveraging the power of CRISPR technology to transform human health, recently…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Trial of SENS-401 Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies for hearing loss, has announced the…
Sensus Healthcare to Showcase Products at AAD Annual Meeting Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive and cost-effective treatments for skin conditions, will showcase its complete line of…
bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive testing for early-stage lung cancer and…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy: Access, Regulations, and Trials Italfarmaco S.p.A. has announced significant progress in the regulatory and clinical development of givinostat, its investigational drug for…
ENCell’s EN001 Gets FDA Orphan Drug Status for Charcot-Marie-Tooth Disease ENCell, a leading biopharmaceutical company specializing in cell and gene therapy, contract research, and manufacturing, has announced that the U.S.…
Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing Elegen, a pioneer in next-generation cell-free DNA manufacturing, has announced a 25% price reduction for its…
FDA Accepts Gazyva sBLA for Lupus Nephritis Treatment Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License…
New Data Supports DNA Vaccine Delivery via Vaxxas’ HD-MAP Technology Vaxxas, a clinical-stage biotechnology company specializing in a novel vaccination platform, announced today the publication of data validating the effectiveness…
Cadrenal Therapeutics Partners with Abbott for Tecarfarin Pivotal Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company specializing in cardiovascular therapeutics, has announced the signing…
FDA Grants Orphan and Pediatric Designations to NEU-001 for Hirschsprung’s Disease Neurenati Therapeutics Inc., a biotechnology company dedicated to pediatric rare diseases, is excited to announce that the U.S. Food…
Centauri Therapeutics Selects First Clinical Candidate for Gram-Negative Infection Treatment Centauri Therapeutics Limited, an immunotherapy company leveraging its unique Alphamer® platform technology, has announced the selection of its first clinical…